Targeted Lung Delivery of Nasally Administered Aerosols

Overview

Journal Aerosol Sci Technol

Date 2014 Jun 17

PMID 24932058

Citations 24

Authors

Geng Tian

Michael Hindle

P Worth Longest

Affiliations

Soon will be listed here.

Abstract

Using the nasal route to deliver pharmaceutical aerosols to the lungs has a number of advantages including co-administration during non-invasive ventilation. The objective of this study was to evaluate the growth and deposition characteristics of nasally administered aerosol throughout the conducting airways based on delivery with streamlined interfaces implementing two forms of controlled condensational growth technology. Characteristic conducting airways were considered including a nose-mouth-throat (NMT) geometry, complete upper tracheobronchial (TB) model through the third bifurcation (B3), and stochastic individual path (SIP) model to the terminal bronchioles (B15). Previously developed streamlined nasal cannula interfaces were used for the delivery of submicrometer particles using either enhanced condensational growth (ECG) or excipient enhanced growth (EEG) techniques. Computational fluid dynamics (CFD) simulations predicted aerosol transport, growth and deposition for a control (4.7 μm) and three submicrometer condensational aerosols with budesonide as a model insoluble drug. Depositional losses with condensational aerosols in the cannula and NMT were less than 5% of the initial dose, which represents an order-of-magnitude reduction compared to the control. The condensational growth techniques increased the TB dose by a factor of 1.1-2.6x, delivered at least 70% of the dose to the alveolar region, and produced final aerosol sizes ≥2.5 μm. Compared to multiple commercial orally inhaled products, the nose-to-lung delivery approach increased dose to the biologically important lower TB region by factors as large as 35x. In conclusion, nose-to-lung delivery with streamlined nasal cannulas and condensational aerosols was highly efficient and targeted deposition to the lower TB and alveolar regions.

Citing Articles

Characterization of Pediatric Extrathoracic Aerosol Deposition with Air-Jet Dry Powder Inhalers.

Thomas M, Bass K, Farkas D, Longest W J Aerosol Sci. 2025; 183.

PMID: 39830599 PMC: 11737425. DOI: 10.1016/j.jaerosci.2024.106474.

Leveraging Numerical Simulation Technology to Advance Drug Preparation: A Comprehensive Review of Application Scenarios and Cases.

Gu Q, Wu H, Sui X, Zhang X, Liu Y, Feng W Pharmaceutics. 2024; 16(10).

PMID: 39458634 PMC: 11511050. DOI: 10.3390/pharmaceutics16101304.

Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part I: In Vitro Testing and Characterization.

Momin M, Farkas D, Hindle M, Hall F, DiBlasi R, Longest W Pharm Res. 2024; 41(8):1703-1723.

PMID: 39112775 PMC: 11362531. DOI: 10.1007/s11095-024-03740-z.

Effect of Nasal Inhalation on Drug Particle Deposition and Size Distribution in the Upper Airway: With Soft Mist Inhalers.

Sadeghi T, Fatehi P, Pakzad L Ann Biomed Eng. 2024; 52(5):1195-1212.

PMID: 38509413 DOI: 10.1007/s10439-023-03423-7.

In-Line Aerosol Therapy via Nasal Cannula during Adult and Paediatric Normal, Obstructive, and Restrictive Breathing.

Mac Giolla Eain M, MacLoughlin R Pharmaceutics. 2023; 15(12).

PMID: 38140020 PMC: 10747070. DOI: 10.3390/pharmaceutics15122679.

References

Longest P, Tian G, Hindle M . Improving the lung delivery of nasally administered aerosols during noninvasive ventilation-an application of enhanced condensational growth (ECG). J Aerosol Med Pulm Drug Deliv. 2011; 24(2):103-18. PMC: 3123840. DOI: 10.1089/jamp.2010.0849. View

Longest P, Hindle M . Numerical Model to Characterize the Size Increase of Combination Drug and Hygroscopic Excipient Nanoparticle Aerosols. Aerosol Sci Technol. 2011; 45(7):884-899. PMC: 3143486. DOI: 10.1080/02786826.2011.566592. View

Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M . Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2004; 169(11):1203-8. DOI: 10.1164/rccm.200308-1111OC. View

Hess D . The mask for noninvasive ventilation: principles of design and effects on aerosol delivery. J Aerosol Med. 2007; 20 Suppl 1:S85-98. DOI: 10.1089/jam.2007.0574. View

Longest P, Holbrook L . In silico models of aerosol delivery to the respiratory tract - development and applications. Adv Drug Deliv Rev. 2011; 64(4):296-311. PMC: 3258464. DOI: 10.1016/j.addr.2011.05.009. View

Hindle M, Longest P . Evaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial model. Pharm Res. 2010; 27(9):1800-11. PMC: 2916966. DOI: 10.1007/s11095-010-0165-z. View

Delvadia R, Hindle M, Longest P, Byron P . In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults. J Aerosol Med Pulm Drug Deliv. 2012; 26(3):138-44. DOI: 10.1089/jamp.2012.0975. View

Patton J, Byron P . Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2006; 6(1):67-74. DOI: 10.1038/nrd2153. View

Golshahi L, Tian G, Azimi M, Son Y, Walenga R, Longest P . The use of condensational growth methods for efficient drug delivery to the lungs during noninvasive ventilation high flow therapy. Pharm Res. 2013; 30(11):2917-30. PMC: 3800269. DOI: 10.1007/s11095-013-1123-3. View

10.

Keck T, Leiacker R, Riechelmann H, Rettinger G . Temperature profile in the nasal cavity. Laryngoscope. 2000; 110(4):651-4. DOI: 10.1097/00005537-200004000-00021. View

11.

Son Y, Longest P, Hindle M . Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Int J Pharm. 2013; 443(1-2):137-45. PMC: 3584634. DOI: 10.1016/j.ijpharm.2013.01.003. View

12.

Patton J, Brain J, Davies L, Fiegel J, Gumbleton M, Kim K . The particle has landed--characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010; 23 Suppl 2:S71-87. DOI: 10.1089/jamp.2010.0836. View

13.

Longest P, Walenga R, Son Y, Hindle M . High-efficiency generation and delivery of aerosols through nasal cannula during noninvasive ventilation. J Aerosol Med Pulm Drug Deliv. 2013; 26(5):266-79. PMC: 3826475. DOI: 10.1089/jamp.2012.1006. View

14.

Longest P, Hindle M . CFD simulations of enhanced condensational growth (ECG) applied to respiratory drug delivery with comparisons to in vitro data. J Aerosol Sci. 2010; 41(8):805-820. PMC: 2935189. DOI: 10.1016/j.jaerosci.2010.04.006. View

15.

Matida E, Finlay W, Breuer M, Lange C . Improving prediction of aerosol deposition in an idealized mouth using large-Eddy simulation. J Aerosol Med. 2006; 19(3):290-300. DOI: 10.1089/jam.2006.19.290. View

16.

Garcia G, Tewksbury E, Wong B, Kimbell J . Interindividual variability in nasal filtration as a function of nasal cavity geometry. J Aerosol Med Pulm Drug Deliv. 2009; 22(2):139-55. DOI: 10.1089/jamp.2008.0713. View

17.

Tgavalekos N, Tawhai M, Harris R, Musch G, Mush G, Vidal-Melo M . Identifying airways responsible for heterogeneous ventilation and mechanical dysfunction in asthma: an image functional modeling approach. J Appl Physiol (1985). 2005; 99(6):2388-97. DOI: 10.1152/japplphysiol.00391.2005. View

18.

Xi J, Longest P . Effects of oral airway geometry characteristics on the diffusional deposition of inhaled nanoparticles. J Biomech Eng. 2008; 130(1):011008. DOI: 10.1115/1.2838039. View

19.

Schroeter J, Garcia G, Kimbell J . Effects of Surface Smoothness on Inertial Particle Deposition in Human Nasal Models. J Aerosol Sci. 2011; 42(1):52-63. PMC: 3039423. DOI: 10.1016/j.jaerosci.2010.11.002. View

20.

Walenga R, Tian G, Longest P . Development of characteristic upper tracheobronchial airway models for testing pharmaceutical aerosol delivery. J Biomech Eng. 2013; 135(9):91010. PMC: 5413171. DOI: 10.1115/1.4024630. View